The 31 references in paper O. Barbarash L., О. Барбараш Л. (2016) “ДЛИТЕЛЬНОСТЬ ДВОЙНОЙ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ // DURATION OF DUAL ANTIPLATELET THERAPY” / spz:neicon:aterotromboz:y:2016:i:1:p:59-68

1
Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J am Coll Cardiol, 2007, 47: 1982-1988.
(check this in PDF content)
2
Sabouret P, Rushton-Smith SK, Kerneis M, Silvan J, Collet J-P, Montalescot G. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J — Cardiovascular Pharmacotherapy, 2015, 1: 198-204.
(check this in PDF content)
3
Montalescot G, Brieger D, Dalby A, Park S-J, Mehran R. Duration of Dual Antiplatelet Therapy after Coronary Stenting. JACC, 2015, 66(7): 832-847.
(check this in PDF content)
4
2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal Advance Access published August 29, 2014. European Heart Journal. doi:10.1093/eurheartj/ehu278.
(check this in PDF content)
5
Сutlip DE, Kereiakes DJ, Mauri L, Stoler R, Dauerman HL. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. J Am Coll Cardiol Intv,2015, 8: 404-410.
(check this in PDF content)
6
Maury L, Hsieh WH, Massaro JM, Ho KK, DAgostino R, Cultup D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Eng J Med, 2007, 356: 1020-1029.
(check this in PDF content)
7
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC, 2014, December 23, 64(24):e139-228.
(check this in PDF content)
8
2011 ACCF/AHA/SCAI Guideline for Percutaneus Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 2011, 124: 574-651.
(check this in PDF content)
9
The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, 345: 494-502.
(check this in PDF content)
10
Yusuf S, Mehta SR, Zhao F et al. For the CURE Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation, 2003, 107: 966-972.
(check this in PDF content)
11
Steinhubl SR, Berger PB, Mann JT3rdet al. For CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288: 2411-2420.
(check this in PDF content)
12
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med,2009, 361: 1045-1057.
(check this in PDF content)
13
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med, 2013, 369: 999-1010.
(check this in PDF content)
14
Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J,2014, 35: 2083-2093.
(check this in PDF content)
15
Campo G, Tebaldi M, Vranckx P et al. Short-versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). J Am Coll Cardiol, 2014, 63: 506-512.
(check this in PDF content)
16
Gwon HC, Hahn J, Park KW, Song YB, Chae IH, Lim DC, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation, 2012, 125: 505-513.
(check this in PDF content)
17
Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, Sharma S, Pocock S, Dangas GD. Duration of dual antiplatelet therapy after drugeluting stent impantation. J Am Coll Cardiol, 2015, 65(13): 1298-1310.
(check this in PDF content)
18
Price MJ. The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. Am Coll Cardiol, 2015, 65(13): 1311-1313.
(check this in PDF content)
19
Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in postmyocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. Eur Heart J. doi: 10.1093/eurheartj/ehu505.
(check this in PDF content)
20
Barbarash OL, Karetnikova VN, Kashtalap VV. The patient after myocardial infarction: how to reduce a risk of recurrent ischemic event? Cardiosomatics, 2015, 6(2): 12-19.
(check this in PDF content)
21
Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non–Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation, 2002, 106: 1690-1695.
(check this in PDF content)
22
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med, 2004, 350(15): 1495-1504.
(check this in PDF content)
23
Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med, 2014, 371: 2155-2166.
(check this in PDF content)
24
Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. JACC, 2015, 65(20): 2211-2221.
(check this in PDF content)
25
Bonaca MP, Bhatt D, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Sabatine MS, Jensen EC. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirinthrombolysis in myocardial infarction 54 (PEGASUSTIMI 54) trial. Am Heart J, 2014, 167: 437-444.e5.
(check this in PDF content)
26
Bonaca MP, Bhatt D, Cohen M, Steg PG, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS for the PEGASUSTIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med.Doi: 10.1056/NEJMoa1500857.
(check this in PDF content)
27
Ubell JA, Bonaca MC, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L et al. Long-term antiplatelaet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative metaanalysis of randomized trials. Eur Hear J,2015. Doi: 10.1093/eurheartj/ehv443.
(check this in PDF content)
28
2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal Advance Access published August 29, 2015. European Heart Journal. Doi:10.1093/eurheartj/ehv320.
(check this in PDF content)
29
Abu-Assi E, Raposeiras-Roubin S, Garcia-Acuna JM, Gonzalez-Juanatey JR. Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World J Cardiol, 2014, 6(11): 1140-1148.
(check this in PDF content)
30
Yeh R, Secemsky E, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ. Individualizing treatment duration of dual antiplatelet therapy after percutaneous coronary intervention: an analysis from the DAPT study. In American Heart Association conference, (2015, November ), Orlando.
(check this in PDF content)
31
Rossello X, Pocock SJ, Julian DG. Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol, 2015 Sep 15, 66(11): 1273-85. doi: 10.1016 /j.jacc.2015.07.018.
(check this in PDF content)